Intrexon Corporation (XON)’s Financial Results Comparing With Kamada Ltd. (NASDAQ:KMDA)

Intrexon Corporation (NASDAQ:XON) and Kamada Ltd. (NASDAQ:KMDA) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intrexon Corporation 160.57M 5.62 509.34M -0.81 0.00
Kamada Ltd. 114.47M 2.14 22.30M 0.55 11.19

In table 1 we can see Intrexon Corporation and Kamada Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Intrexon Corporation -317.21% -35% -22.1%
Kamada Ltd. 19.48% 0% 0%

Analyst Ratings

The Recommendations and Ratings for Intrexon Corporation and Kamada Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Intrexon Corporation 0 0 0 0.00
Kamada Ltd. 0 0 1 3.00

Insider & Institutional Ownership

Institutional investors owned 86.7% of Intrexon Corporation shares and 32.38% of Kamada Ltd. shares. About 0.6% of Intrexon Corporation’s share are owned by insiders. On the other hand, insiders owned about 20.83% of Kamada Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Intrexon Corporation -51.18% -45.95% -57.36% -73.55% -67.91% -36.7%
Kamada Ltd. 0.9% 17.24% 18.59% 5.21% 17.24% 23.1%

For the past year Intrexon Corporation has -36.7% weaker performance while Kamada Ltd. has 23.1% stronger performance.

Summary

On 9 of the 12 factors Kamada Ltd. beats Intrexon Corporation.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra, a hepatitis B immunoglobulin; Hepatect CP, a hepatitis B immunoglobulin; and Megalotect, a CMV immunoglobulin. The company also provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. In addition, it offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; Human Transferrin for diagnostic assays and cell cultures; and coagulation factors comprising Factor VIII and Factor IX. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, graft-versus-host diseases, and transplantations. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.